What recent development has Autonomix Medical announced regarding its clinical trials?

Autonomix Medical, Inc. recently announced positive follow-up data from its ongoing proof-of-concept clinical trial evaluating a new nerve-targeted treatment for pancreatic cancer pain.

Who discussed Autonomix's recent clinical trial data, and where was this information shared?

Dr. Robert Schwartz, the Chief Medical Officer of Autonomix, discussed the 4-6 week positive follow-up data during a Virtual Investor segment.

What is the key technological advancement that Autonomix Medical is developing for nerve-targeted treatments?

The company's technology includes a catheter-based microchip sensing array that detects neural signals with 3,000 times greater sensitivity than existing technologies.

What specific medical condition is Autonomix targeting with its nerve-targeted treatment technology?

Autonomix is initially focused on treating pancreatic cancer pain, which is known to be debilitating and currently has no reliable solution.

Is Autonomix's technology currently available for marketing in the U.S. and what are its intended applications?

Autonomix Medical's investigational technology has not yet been cleared for marketing in the United States but aims to address various indications beyond pancreatic cancer pain.

Autonomix Medical, Inc.'s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial

10/30/24 8:30:00 AM ET

$AMIX

Medical/Dental Instruments

Health Care

Get the next $AMIX alert in real time by email

Access the Virtual Investor "What This Means" Segment here

THE WOODLANDS, TX, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it recently participated in a Virtual Investor "What This Means" segment.

For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company's recently announced 4-6 week positive follow-up data, from the first five "lead-in" patients in the Company's ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.

The "What This Means" segment can be accessed here.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact

JTC Team, LLC

Jenene Thomas

908-824-0775

[email protected]

Get the next $AMIX alert in real time by email

Autonomix Medical, Inc.'s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial

Chat with this insight

Q&A

What recent development has Autonomix Medical announced regarding its clinical trials?

Who discussed Autonomix's recent clinical trial data, and where was this information shared?

What is the key technological advancement that Autonomix Medical is developing for nerve-targeted treatments?

What specific medical condition is Autonomix targeting with its nerve-targeted treatment technology?

Is Autonomix's technology currently available for marketing in the U.S. and what are its intended applications?

Recent Analyst Ratings for
$AMIX

$AMIX
Leadership Updates

Live Leadership Updates

Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

Autonomix Appoints Jennifer Cook as Chief Business Officer

$AMIX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Autonomix Medical Inc.

SEC Form SC 13D filed by Autonomix Medical Inc.

$AMIX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Robins David Andrew

SEC Form 4 filed by Director Bisson Lori

SEC Form 4 filed by Director Klemp Walter V

$AMIX
Press Releases

Fastest customizable press release news feed in the world

Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients' 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction